Flow cytometry analysis of human CD45 positive leukemia cells showed that compared with single agent groups, the combination group significantly reduced the tumor burden in both the bone marrow and PBMCs (Supplementary Fig. S5B-C). This evidence concerns the gene PTPRC and leukemia.